New blood test can predict breast cancer recurrence years before detection

Researchers from the Institute of Cancer Research (ICR) have announced a groundbreaking blood test that can predict the recurrence of breast cancer years before it is detectable on scans.

This “ultra-sensitive” test identifies traces of tumor DNA well before a full relapse, making it easier to treat.

Referred to as the “liquid biopsy,” the test was 100% accurate in forecasting which patients would experience a recurrence of cancer, allowing for earlier intervention.

According to findings presented at the American Society of Clinical Oncology conference in Chicago, the blood test typically detected cancer 15 months before symptoms appeared or it was visible on scans, with the earliest detection being 41 months ahead of a scan-confirmed diagnosis.